Stroke Clinical Trials

Find Stroke Clinical Trials Near You

Assessment of the Safety and Effectiveness of the VARIPULSE™ Catheter System in the Treatment of Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein (With or Without Posterior Wall Isolation) and Superior Vena Cava Isolation: A Randomized Controlled Trial

Status: Recruiting
Location: See all (11) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to assess how safe VARIPULSE catheter system is for treatment of a heart rhythm disease called persistent atrial fibrillation (PsAF) in participants who are having a catheter ablation procedure (treat heart rhythm disease). This includes isolation of pulmonary vein and superior vena cava (heart veins; pulmonary vein isolation \[PVI\] and superior vena cava isolation \[SVCI\]), with or without another technique called posterior wall isolation (PWI). Also, to assess how safe it is for participants who are having a catheter ablation procedure and at the same time receiving another procedure called left atrial appendage occlusion (LAAO; to reduce stroke risk). Additionally, to assess how well VARIPULSE catheter system works over a long period of time for treatment of PsAF in participants undergoing catheter ablation for PVI, SVCI and SVCI+PWI.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Participant has been diagnosed with symptomatic persistent atrial fibrillation (PsAF), which is defined as continuous atrial fibrillation (AF) sustained beyond 7 days in duration and less than 365 days in duration, documented by: i. A physician's note documenting diagnosis of symptomatic PsAF, as defined above; and ii. Two electrocardiograms (ECGs) showing continuous AF, with electrocardiogram taken at least 7 days apart (electrocardiograms cannot be greater than (\>) 365 days prior to enrollment); or iii. A 24-hour arrhythmia monitor documenting continuous AF within the last 365 days

• Participant is aged 18 - 80 years at the time of informed consent

• Participant is willing and capable of providing informed consent

• Participant is able and willing to comply with all pre-, post- and follow-up testing and requirement

⁃ Left atrial appendage occlusion (LAAO) concomitant subset:

⁃ \- Participant is clinically indicated for a LAAO procedure

Locations
United States
Alabama
Grandview Medical Center
RECRUITING
Birmingham
Arkansas
Arrhythmia Research Group
RECRUITING
Jonesboro
Arizona
Pima Heart and Vascular
RECRUITING
Tucson
California
Pacific Heart Institute Cedars Sinai Medical Center
RECRUITING
Santa Monica
Colorado
Aurora Denver Cardiology Associates
RECRUITING
Aurora
Connecticut
Hartford Hospital
RECRUITING
Hartford
Kentucky
Saint Elizabeth Medical Center
RECRUITING
Edgewood
New York
Albert Einstein College Of Medicine - Montefiore Medical Center
RECRUITING
The Bronx
Oklahoma
Oklahoma Heart Hospital
RECRUITING
Oklahoma City
Pennsylvania
Penn Presbyterian Medical Center
RECRUITING
Philadelphia
Wisconsin
Mercy Hospital
RECRUITING
Janesville
Contact Information
Primary
Narvelle Delabruere
NDelabru@its.jnj.com
949-933-1710
Backup
Josiah M Gillespie
jgille12@its.jnj.com
405-924-0777
Time Frame
Start Date: 2026-08-26
Estimated Completion Date: 2031-08-24
Participants
Target number of participants: 1070
Treatments
Experimental: VARIPULSE Catheter System: PVI and SVCI
Participants with persistent atrial fibrillation (PsAF) undergoing catheter ablation for the first-time with the VARIPULSE Catheter System will undergo the ablation procedure for PVI and SVCI.~Additionally, a subset of participants will undergo a concomitant left atrial appendage occlusion (LAAO) procedure. All participants will be followed for up to 36 months post procedure.
Experimental: VARIPULSE Catheter System: PVI and SVCI + PWI
Participants with PsAF undergoing catheter ablation for the first-time with VARIPULSE catheter system will undergo the ablation procedure for PVI and SVCI along with posterior wall isolation (PWI). Additionally, a subset of participants will undergo a concomitant LAAO procedure. All participants will be followed for up to 36 months post procedure.
Sponsors
Leads: Biosense Webster, Inc.

This content was sourced from clinicaltrials.gov